Fresenius Medical Care advances to multi?month high, Goldman optimism lifts shares

Fresenius Medical Care benefits from upbeat analyst commentary as Goldman Sachs highlights earnings momentum ahead of the August quarterly update, while the DAX-listed dialysis group’s shares touch their highest level since February in Frankfurt trading.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 17:53.

Fresenius Medical Care (DE0005785802) extended recent gains on Xetra at the start of the week. According to a market report citing Goldman Sachs, the DAX dialysis specialist’s shares touched 41.58 euros on Monday, their highest level since February.

Goldman sees earnings momentum

The Marketscreener summary of broker comments notes that Goldman analyst Richard Felton expects Fresenius Medical Care to show a further solid improvement in operating profit in the upcoming quarterly report in early August. The report highlights that the broker remains optimistic about operational progress despite the recent share price recovery.

On Monday afternoon in Frankfurt, finanzen.net quoted Fresenius Medical Care at around 41.26 euros, up roughly 1.3 percent on the day and close to the intraday high mentioned in the broker report. The move leaves the shares trading markedly above levels seen in spring, when they were still in the mid-30-euro range.

Analyst views remain mixed

While Goldman Sachs is constructive on the near-term earnings trend, not all analysts share the same stance. UBS reiterated a “Sell” rating on Fresenius Medical Care on 1 June, with a price target of 37 euros, according to finanzen.ch. At the time of that note, the shares were trading around 41.18 euros, already above the Swiss bank’s target.

The UBS update underscores the valuation debate around the stock after its recovery. The analysis points to downside versus the current quotation, even as operational metrics improve, illustrating the spread between more cautious and more optimistic research-house assessments.

The dialysis business model

Fresenius Medical Care generates most of its revenue with dialysis services for patients suffering from chronic kidney failure, complemented by the sale of dialysis machines and related disposables. The group operates a global network of dialysis clinics and supplies equipment and consumables to third-party providers.

Where the shares trade today

The Fresenius Medical Care shares (DE0005785802) traded on Xetra on 2026-06-22 at 17:30 at 41.26 euros.

Key data on the Fresenius Medical Care shares

• Company: Fresenius Medical Care AG
• ISIN: DE0005785802
• WKN: 578580
• Ticker: FME
• Trading venue: Xetra
• Price (as of 2026-06-22, 17:30): 41.26 EUR
• Market cap: 12.0 billion EUR (as of 2026-06-22)
• Sector / industry: Health Care / Medical Services
• Index membership: DAX
• Next earnings date: 2026-08-06

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.